Trial Search Results
Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.
Stanford is currently accepting patients for this trial.
- Drug: Omecamtiv Mecarbil
- Drug: Placebo
Key Inclusion Criteria:
- Subject has provided informed consent
- Male or female, ≥ 18 to ≤ 85 years
- History of chronic HF (defined as requiring treatment for HF for a minimum of 30 days
- LVEF ≤ 35%, per subjects most recent medical record, within 12 months prior to
- NYHA class II to IV at most recent screening assessment.
- Managed with HF SoC therapies consistent with regional clinical practice guidelines
according to investigator judgment of subject's clinical status
- Current hospitalization with primary reason of HF OR one of the following events
within 1 year of screening: hospitalization with primary reason of HF; urgent visit to
emergency department (ED) with primary reason of HF.
- Elevated BNP or NT-proBNP
Other Inclusion Criteria May apply
Key Exclusion Criteria:
- Currently receiving treatment in another investigational device or drug study, or < 30
days since ending treatment on another investigational device or drug study(ies).
Other investigational procedures while participating in this study are excluded.
- Malignancy within 5 years prior to randomization with the following exceptions:
localized basal or squamous cell carcinoma of the skin, cervical intraepithelial
neoplasia, stage 1 prostate carcinoma, breast ductal carcinoma in situ.
- Subject has known sensitivity to any of the products or components to be administered
Other Exclusion Criteria May apply
Ages Eligible for Study
18 Years - 85 Years
Genders Eligible for Study